There is no current cure for progressive Multiple Sclerosis (MS).
With Lucid-MS, there is hope to cure progressive MS.
FSD Pharma, a life sciences holding company dedicated to building a portfolio of wellness and biotech solutions, is working to bring hope to millions of patients suffering from some of the world’s most challenging medical conditions.
With a diversified approach to addressing “Total Brain Health,” FSD’s mission is to bring cutting-edge therapies to market to help those suffering from neurodegenerative and neuropsychiatric disorders. Since its inception, FSD has been developing a proprietary formulation that enhances the anti-inflammatory properties of PEA, a fatty acid amide currently used as a dietary supplement. Now, through its new, wholly-owned subsidiary, Lucid Psycheceuticals, FSD also has the exclusive worldwide rights to patented compounds developed by the world-renowned University Health Network, which offer the potential to treat the underlying cause of progressive Multiple Sclerosis (“MS”). Additionally, FSD is developing a unique psychedelic-based therapy aimed to help the millions suffering from mental health conditions, a multibillion-dollar market and growing, only exacerbated by impacts from the COVID-19 global pandemic.
With the acquisition of Lucid and the leadership of a highly-accomplished team with deep management and biosciences experience, FSD Pharma is strategically positioned to advance a strong pipeline of clinical central nervous system-focused (CNS) drug candidates, which include:
- Lucid-PSYCH: a novel psychoactive molecule currently undergoing IND-enabling studies and targeted for the treatment of neuropsychiatric disorders, such as Major Depressive Disorder.
- Lucid-MS:a patented neuroprotective new chemical entity (NCE) that has shown in preclinical models, to potentially prevent and reverse myelin degradation, an underlying cause of Multiple Sclerosis and other neurodegenerative orders.
- FSD-PEA: an ultra-micro-PEA compound with the potential to address a range of inflammatory conditions. FSD-PEA has completed phase 1 FDA approved trials with positive topline results, and indications for phase 2 are currently being evaluated.
Large and Growing Market Opportunities: Addressing Significant Unmet Medical Needs
According to the World Health Organization, Depression is the leading cause of disability worldwide and is a major contributor to the overall global burden of chronic disease. In the United States alone, it affects approximately 17.3 million adults, or about 7% of the population aged 18 and older. Of those, about 35% do not respond to current drug treatments. For the first time in decades, the emergence of new psychedelic therapies holds the promise of potentially changing that paradigm. As a result, a growing number of psychedelic therapeutic companies are now publicly traded and valued well beyond US$1 billion, given the immense promise and demonstrated impact of such treatments.
Multiple Sclerosis is a chronic inflammatory and degenerative central nervous system disorder with no current cure. MS, a chronic inflammatory and degenerative central nervous system disorder with no current cure, affects approximately 2.5 million people worldwide. This condition damages nerves and can lead to debilitating cognitive and physical degradation. Today’s global MS treatment market is valued at US$23 billion.
Amid the COVID-19 crisis, the global market for anti-Inflammatory therapeutics was estimated at US$98 billion in 2020. The rising incidence of acute and chronic diseases is expected to drive that already large treatment market opportunity even further, with it projected to reach over US$130 billion by 2026.
Additional FSD Highlights
- A strong balance sheet represented by no debt and over USD$43.2 million in cash as of June 30, 2021.
- Well-positioned to advance current pipeline and aggressively pursue additional acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on Total Brain Health.
- Renowned clinical team led by Dr. Lakshmi P. Kotra, Senior Scientist at Krembil Brain Institute, University Health Network (UHN), and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra serves as CEO of FSD Pharma’s wholly-owned subsidiary, Lucid Psycheceuticals.
With experienced leadership, a diverse pipeline of clinical assets accompanied by exclusive licensing rights, and therapies advancing to treat pervasive medical conditions, like inflammation, MS, and Depression, FSD Pharma is on a strong trajectory for growth. To learn more, visit https://fsdpharma.com/.